ESPR Esperion Therapeutics Inc.

Esperion to Participate in January Investor Meetings

Esperion to Participate in January Investor Meetings

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th, 2023 in San Francisco, California.

J.P. Morgan 41st Annual Healthcare Conference

Sheldon Koenig, CEO, will be making a corporate presentation and hosting 1x1 institutional investor meetings.

Date/Time: January 11th, 2023, 1:30pm PT

Location: The Westin St. Francis Hotel in San Francisco; Georgian Room

Click to access the webcast.

LifeSci Partners 12th Annual Corporate Access Event

Sheldon Koenig, CEO, Ben Halladay, CFO, and JoAnne Foody, CMO, will be hosting 1x1 institutional investor meetings.

Date/Time: January 9-10th, 2023

Location: Beacon Grand Hotel in San Francisco

To schedule a meeting on the online system managed by LifeSci Partners, please click to register for the conference.

Esperion Therapeutics

Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit and follow us on Twitter at /EsperionInc.

Contact:

Esperion Corporate Communications



EN
13/12/2022

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Jefferies Global Healthcare Conference - Lo...

Esperion to Participate in Jefferies Global Healthcare Conference - London ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET). The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsp...

18h / 55m 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Host Virtual Investor Key Opinion Leader Event Highlightin...

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. – Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event for investors to discuss the clinical and real-world challenges of statin intolerance, its impact on patient outcomes, and the Company’s continued commitment to addressing th...

October 28, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at...

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025. Oral Presentation Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trialNovember 9, 2025, 9:45 – 11:00 AM CSTPresenter: Carolina Pires Zin...

October 27, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Report Third Quarter 2025 Financial Results on November 6

Esperion to Report Third Quarter 2025 Financial Results on November 6 ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call ...

October 23, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Nominates ESP-2001 as Preclinical Development Candidate for T...

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis – Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ESP-2001 Has the Potential to Meaningfully Impact the Progression of PSC, a Disease with No Approved Treatments – ANN ARBOR, Mich., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the nomination of ESP-2001, the Company’s highly-specific allosteric ATP citra...

October 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch